Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.

The main objective of this study was to evaluate the role of the recent World Health Organization (WHO) classification for assessing prognosis in patients with myelodysplastic syndromes (MDS). To this effect, we analyzed the prognostic impact of the WHO and French-American-British (FAB) morphologic classifications and of four different scoring systems in a series of 311 patients with primary MDS diagnosed between October 1990 and June 2001. Both the FAB and WHO classifications identified groups with different prognoses (p<0.0001), those presenting refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS) showing the best prognosis. The WHO classification subdivided RA into RA with only red cell dysplasia, and refractory cytopenia with multilineage dysplasia (RCMD), and RARS into RARS plus refractory cytopenia with multilineage dysplasia and ringed sideroblast (RCMD-RS). In our population, we have shown that the two subtypes characterized by dysplasia affecting exclusively the erythroid population (RA and RARS) have a better prognosis, with a median survival of 122.2 and 81.9 months, respectively, than those with multilineage dysplasia (RCMD and RCMD-RS) with a median survival of 32.3 and 43.2 months, respectively. There were no significant differences in median survival comparing RA with RAS (p<0.95), or comparing RCMD with RSCMD (p<0.97). Besides, the four scoring systems discriminated our MDS patients in terms of survival, and an increase in prognostic capacity was achieved on adding the score to the morphological classifications. Risk scoring had a greater prognostic impact than the FAB and WHO classifications. Prognostic scoring systems may be an important tool for risk stratification in hematological practice, and add significance to morphological classification. Combined application of the WHO classification and score system is useful for improving the identification of patients with a poorer prognosis. The WHO classification establishes more homogeneous subcategories than the FAB classification and is also able to identify groups with different prognoses.

[1]  H. Chi,et al.  Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome , 2003, Leukemia.

[2]  D. Head.  Problematic WHO Reclassification of Myelodysplastic Syndromes , 2000 .

[3]  U. Germing,et al.  Two types of acquired idiopathic sideroblastic anaemia (AISA): a time‐tested distinction , 2000, British journal of haematology.

[4]  P. Martiat,et al.  Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome? , 1993, Leukemia & lymphoma.

[5]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[6]  N. Gattermann,et al.  Two types of acquired idiopathic sideroblastic anaemia (AISA) , 1990, British journal of haematology.

[7]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[8]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. Jinnai,et al.  Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia , 1998, Leukemia.

[10]  N. Gattermann,et al.  From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. , 2000, Leukemia research.

[11]  Robert B Howe,et al.  The WHO classification of MDS does make a difference. , 2004, Blood.

[12]  E. Estey,et al.  The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes. , 1995, Leukemia & lymphoma.

[13]  D. Cox.  Regression Models and Life-Tables , 1972 .

[14]  M. Seabright.  A rapid banding technique for human chromosomes. , 1971, Lancet.

[15]  M. Tomonaga,et al.  Morphological comparison of dysplastic changes between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastic syndromes. , 1995, Leukemia research.

[16]  P. Thall,et al.  Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. , 1997, Blood.

[17]  Z. Zemanová,et al.  The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia. , 2005, Leukemia research.

[18]  E. Ascari,et al.  Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes , 1998, Leukemia.

[19]  U. Germing,et al.  Increasing incidence of myelodysplastic syndromes: real or fictitious? , 1998, Leukemia research.

[20]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[21]  R. Larson,et al.  Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. , 1996, Leukemia.

[22]  M. Tomonaga,et al.  New system for assessing the prognosis of refractory anemia patients , 1999, Leukemia.

[23]  D. Steensma,et al.  The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. , 2003, Leukemia research.

[24]  U. Germing,et al.  Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.

[25]  U. Germing,et al.  Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. , 1994, Leukemia.

[26]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[27]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.

[28]  A. Julià,et al.  Myelodysplastic syndromes: a study of 101 cases according to the FAB classification , 1985, British journal of haematology.

[29]  K. Metze,et al.  Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. , 2004, Leukemia research.

[30]  H. Gralnick,et al.  The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group , 1994, British journal of haematology.

[31]  U. Germing,et al.  Problems in the classification of CMML--dysplastic versus proliferative type. , 1998, Leukemia research.

[32]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[33]  M. Pfeilstöcker,et al.  Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. , 2001, Blood.

[34]  J. Goasguen,et al.  Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). , 1992, Leukemia research.

[35]  K. Michalová,et al.  Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. , 2004, Leukemia research.

[36]  U. Germing,et al.  Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.

[37]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .